Anika (ANIK) Signs Distribution Agreement with DePuy Mitek for MONOVISC
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Join SI Premium – FREE
Anika Therapeutics, Inc. (Nasdaq: ANIK) has signed an exclusive, multi-year U.S. licensing and supply agreement with DePuy Mitek, Inc., a leading orthopedic sports medicine company, for Anika’s MONOVISC, a highly purified, high molecular weight form of hyaluronic acid for treating pain in patients suffering from osteoarthritis of the knee.
In connection with the entering into of the agreement, Anika will receive an initial payment of $2.5 million. Anika also will be entitled to receive additional payments from DePuy Mitek, following the mutual decision to launch the product, related to future regulatory, clinical, and sales milestones. The MONOVISC product is currently pending approval by the U.S. Food and Drug Administration.
In connection with the entering into of the agreement, Anika will receive an initial payment of $2.5 million. Anika also will be entitled to receive additional payments from DePuy Mitek, following the mutual decision to launch the product, related to future regulatory, clinical, and sales milestones. The MONOVISC product is currently pending approval by the U.S. Food and Drug Administration.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Aptevo reports 93% clinical benefit rate in TP53-mutated AML trial
- Dubai's VARA and Securitize sign MoU on tokenized markets
- Estée Lauder Companies names new brand leadership after retirement
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
